Filing Flows › Xenetic Biosciences (XBIO) › Q4 2024
Xenetic Biosciences (XBIO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 18, 2025
Xenetic Biosciences (XBIO) reported revenue of $649K for the fourth quarter 2024 (Q4 2024), -3% from a year earlier and +6% from the quarter before. Operating margin was -169.4%, net loss $1.1M (162.5% of revenue).
Xenetic Biosciences, Q4 2024: revenue $649K (-3% year over year), operating margin -169.4%, net loss $1.1M, operating cash flow −$674K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $649K | +6% | -3% |
| Operating profit | −$1.1M | — | — |
| Net earnings | −$1.1M | — | — |
| Operating cash flow | −$674K | — | — |
What changed
Revenue was $649K in Q4 2024, down 3% year over year and up 6% from the previous quarter.
Operating costs exceeded revenue by $1.1M, an operating margin of -169.4%. Total costs fell 9% while revenue fell 3%. The quarter ended with a net loss of $1.1M, wider than the previous quarter's $437K loss.
Operating cash flow was −$674K. Non-cash charges added back $25K of share-based compensation. Working capital and other items added $355K.
Questions
What was Xenetic Biosciences' revenue in the fourth quarter 2024?
Xenetic Biosciences (XBIO) reported revenue of $649K for the fourth quarter 2024 (Q4 2024), -3% from a year earlier and +6% from the quarter before.
Was Xenetic Biosciences profitable in the fourth quarter 2024?
Operating loss was $1.1M (-169.4% of revenue) and net loss $1.1M.